ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,794Medicare Part D Prescriptions Filled, Including Refills

Rank: 22 out of 247

$698K Total Retail Price of All Prescriptions

Rank: 12 out of 247

245 Patients Receiving at Least One Drug in Part D
87%Patients 65 Years and Older
71% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maine
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 245 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

2% of this provider’s 7,768 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

28% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$79 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

36 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maine
ATENOLOL 387 359 1 10
SIMVASTATIN 378 337 2 1
PANTOPRAZOLE SODIUM 320 275 3 19
OMEPRAZOLE 279 234 4 4
SERTRALINE HCL 250 224 5 16
LEVOTHYROXINE SODIUM 238 228 6 3
METOPROLOL SUCCINATE 217 195 7 14
LOSARTAN POTASSIUM 210 179 8 15
LISINOPRIL 181 155 9 2
METHENAMINE HIPPURATE 163 160 10 149
NAMENDA 155 155 11 47
AMLODIPINE BESYLATE 150 140 12 6
WARFARIN SODIUM 149 144 13 13
DIOVAN 130 114 14 38
ADVAIR DISKUS 124 102 15 18
ATORVASTATIN CALCIUM 122 114 16 8
FUROSEMIDE 120 109 17 5
TAMSULOSIN HCL 112 109 18 31
FINASTERIDE 104 100 19 73
DONEPEZIL HCL 104 104 19 35
PRAVASTATIN SODIUM 103 91 21 23
ZETIA 101 84 22 62
CITALOPRAM HBR 99 94 23 20
LANTUS 99 99 23 39
FLUOXETINE HCL 98 88 25 49
RISPERIDONE 98 82 25 58
RANITIDINE HCL 92 83 27 34
LISINOPRIL-HYDROCHLOROTHIAZIDE 91 85 28 51
ALENDRONATE SODIUM 86 82 29 32
PREDNISONE 84 65 30 21
ZOSTAVAX 82 76 31 59
LOVASTATIN 81 81 32 22
METFORMIN HCL 74 67 33 12
MICARDIS 73 73 34 194
GABAPENTIN 70 57 35 17
SPIRONOLACTONE 70 54 35 53
CLOPIDOGREL 69 69 37 70
TERAZOSIN HCL 68 67 38 86
OLANZAPINE 66 62 39 106
AMITRIPTYLINE HCL 65 50 R 40 55
VYTORIN 65 65 40 155
SOTALOL 64 52 42 130
MIRTAZAPINE 63 55 43 46
DOXAZOSIN MESYLATE 62 59 44 57
METOPROLOL TARTRATE 59 55 45 7
SPIRIVA 58 45 46 26
PAROXETINE HCL 57 52 47 45
SINGULAIR 55 44 48 109
COMBIVENT 51 43 49 63
HYDROCHLOROTHIAZIDE 51 48 49 9
CRESTOR 51 51 49 30
DIOVAN HCT 50 50 52 96
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 5, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.